Sage Therapeutics, Inc. (NASDAQ:SAGE) has been given a $82.00 target price by equities researchers at SunTrust Banks, Inc. in a note issued to investors on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks, Inc.’s price objective would indicate a potential upside of 29.13% from the stock’s current price.

A number of other research firms have also recently commented on SAGE. J P Morgan Chase & Co reduced their price target on shares of Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating for the company in a report on Tuesday, September 12th. Canaccord Genuity reduced their price target on shares of Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a report on Tuesday, September 12th. Cowen and Company reduced their price target on shares of Sage Therapeutics from $100.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, September 12th. Stifel Nicolaus began coverage on shares of Sage Therapeutics in a report on Wednesday, August 9th. They issued a “buy” rating and a $104.00 price target for the company. Finally, BidaskClub cut shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $86.79.

Shares of Sage Therapeutics (SAGE) opened at 63.50 on Thursday. The company has a 50-day moving average of $67.78 and a 200 day moving average of $74.13. The company’s market capitalization is $2.38 billion. Sage Therapeutics has a 52-week low of $38.30 and a 52-week high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.25). During the same period last year, the business posted ($1.08) EPS. Analysts predict that Sage Therapeutics will post ($7.40) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/sage-therapeutics-inc-sage-given-a-82-00-price-target-by-suntrust-banks-inc-analysts/1644531.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in shares of Sage Therapeutics by 5.9% during the second quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after purchasing an additional 168,424 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Sage Therapeutics by 2.2% during the second quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after purchasing an additional 58,679 shares in the last quarter. State Street Corp lifted its position in shares of Sage Therapeutics by 7.7% during the second quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after purchasing an additional 87,097 shares in the last quarter. Pictet Asset Management Ltd. lifted its position in shares of Sage Therapeutics by 12.2% during the second quarter. Pictet Asset Management Ltd. now owns 480,013 shares of the biopharmaceutical company’s stock valued at $31,734,000 after purchasing an additional 52,124 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Sage Therapeutics by 17.9% during the second quarter. Northern Trust Corp now owns 411,444 shares of the biopharmaceutical company’s stock valued at $32,767,000 after purchasing an additional 62,474 shares in the last quarter.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.